GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Open accessThe DOI matches its Crossref record; 204 of the 216 references it cites were found in a registry or an index.
Abstract
Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke. The cardiovascular benefits observed following GLP-1RA treatment could be secondary to improvements in glycemia, blood pressure, postprandial lipidemia, and inflammation. Yet, the GLP-1R is also expressed in the heart and vasculature, suggesting that GLP-1R agonism may impact the cardiovascular system. The emergence of GLP-1RAs combined with glucose-dependent insulinotropic polypeptide and glucagon receptor agonists has shown promising results as new weight loss medications. Dual-agonist and tri-agonist therapies have demonstrated superior outcomes in weight loss, lowered blood sugar and lipid levels, restoration of tissue function, and enhancement of overall substrate metabolism compared to using GLP-1R agonists alone. However, the precise mechanisms underlying their cardiovascular benefits remain to be fully elucidated. This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and tri-agonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects. It also addresses current gaps in understanding and areas for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, emerging reviews highlight the absence of cardiovascularoutcomes data and the necessity to evaluate pancreatic, hepatic, and cardiometabolic safety under prolonged GLP-1/GIP/GCGR stimulation before establishing retatrutide as a long-term therapeutic standard.46”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, GLP-1 receptor agonists and tirzepatide improve multiple cardiometabolic pathways, including glycaemic control, blood pressure, inflammation, endothelial function, insulin sensitivity, and renal physiology, suggesting that both weight-loss-dependent and weight-loss-independent mechanisms likely contribute to their CV effects.[16][17][18]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2D, CV, and HF benefits associated with incretin-based therapies are likely mediated only partly by intentional weight loss.”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
International Journal of Molecular Sciences
(2024) · International Journal of Molecular Sciences · doi:10.3390/ijms · Cited by 10,111
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Journal of The American College of Cardiology
(2015) · Wilderness & Environmental Medicine · doi:10.1016/j.wem.2015.03.023 · Cited by 2,584
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Rao, S. V., & Jollis, J. G. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.10.991 · Cited by 2,217
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Molecular and cellular endocrinology
(1995) · Journal of Endocrinology · doi:10.1677/joe.0.147so19 · Cited by 1,991
High blood pressure and cardiovascular disease
Fuchs, F. D., & Whelton, P. K. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14240 · Cited by 1,948
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
(2019) · Nature Communications · doi:10.1038/41467.2041-1723 · Cited by 1,914
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
The journal of clinical investigation
(1994) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(94)92394-9 · Cited by 1,198
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
The NEW ENGLAND JOURNAL of MEDICINE
Gelijns, A. C., Rosenberg, N., & Moskowitz, A. J. (2009) · Studies on Science and the Innovation Process · doi:10.1142/9789814273596_0013 · Cited by 980
British Journal of Pharmacology
(2010) · British Journal of Pharmacology · doi:10.1111/(issn)1476-5381 · Cited by 920
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
Science Translational Medicine
(2013) · Science Translational Medicine · doi:10.1126/scitranslmed · Cited by 859
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
European Journal of Clinical Investigation
(2010) · European Journal of Clinical Investigation · doi:10.1111/(issn)1365-2362 · Cited by 632
The changing face of diabetes complications
Gregg, E. W., Sattar, N., & Ali, M. K. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30010-9 · Cited by 612
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
The Canadian Journal of Cardiology.
Taylor, J. H. (2012) · PubMed · Cited by 590
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243312 · Cited by 534
Nikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
THE JOURNAL OF BIOLOGICAL CHEMISTRY
Clarke, H. T. (1955) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)81402-3 · Cited by 498
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470
Journal of Diabetes and Its Complications
Fonseca, V. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.002 · Cited by 463
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Intestinal Factors in the Control of Insulin Secretion
McINTYRE, N., HOLDSWORTH, C. D., & TURNER, D. S. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1317 · Cited by 381
DiGruccio, M. R., Mawla, A. M., Donaldson, C. J., Noguchi, G. M., Vaughan, J., Cowing-Zitron, C., van der Meulen, T., & Huising, M. O. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.007 · Cited by 353
A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence
Brown, J. C., & Dryburgh, J. R. (1971) · Canadian Journal of Biochemistry · doi:10.1139/o71-122 · Cited by 344
Jin, S. ‐. C., Han, V. K. M., Simmons, J. G., Towle, A. C., Lauder, J. M., & Lund, P. K. (1988) · Journal of Comparative Neurology · doi:10.1002/cne.902710405 · Cited by 335
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Self-citationWong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Helmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000615456.97862.30 · Cited by 283
Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
Boland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0209-6 · Cited by 270
Nature Reviews Endocrinology at 15
(2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00421-w · Cited by 270
Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors1
Bollag, R. J., Zhong, Q., Phillips, P., Min, L., Zhong, L., Cameron, R., Mulloy, A. L., Rasmussen, H., Qin, F., Ding, K. H., et al. (2000) · Endocrinology · doi:10.1210/endo.141.3.7366 · Cited by 265
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259
Liraglutide causes large and rapid epicardial fat reduction
Iacobellis, G., Mohseni, M., Bianco, S. D., & Banga, P. K. (2017) · Obesity · doi:10.1002/oby.21718 · Cited by 251
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223
Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02526-x · Cited by 215
Journal of Neuroscience Research
(2006) · Journal of Neuroscience Research · doi:10.1002/(issn)1097-4547 · Cited by 208
Effects of glucose-dependent insulinotropic peptide on osteoclast function
Zhong, Q., Itokawa, T., Sridhar, S., Ding, K.-H., Xie, D., Kang, B., Bollag, W. B., Bollag, R. J., Hamrick, M., Insogna, K., et al. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00364.2006 · Cited by 206
British Journal of Clinical Pharmacology
(2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04428.x · Cited by 200
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199
Do the Apoe −/− and Ldlr −/– Mice Yield the Same Insight on Atherogenesis?
Getz, G. S., & Reardon, C. A. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306874 · Cited by 198
Preproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194
Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194
Nyberg, J., Anderson, M. F., Meister, B., Alborn, A.-M., Ström, A.-K., Brederlau, A., Illerskog, A.-C., Nilsson, O., Kieffer, T. J., Hietala, M. A., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4920-04.2005 · Cited by 191
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
A genetic map of the mouse dorsal vagal complex and its role in obesity
Ludwig, M. Q., Cheng, W., Gordian, D., Lee, J., Paulsen, S. J., Hansen, S. N., Egerod, K. L., Barkholt, P., Rhodes, C. J., Secher, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00363-1 · Cited by 186
Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182
Poornima, I., Brown, S. B., Bhashyam, S., Parikh, P., Bolukoglu, H., & Shannon, R. P. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
Jorsal, T., Rhee, N. A., Pedersen, J., Wahlgren, C. D., Mortensen, B., Jepsen, S. L., Jelsing, J., Dalbøge, L. S., Vilmann, P., Hassan, H., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4450-9 · Cited by 172
Nie, Y., Nakashima, M., Brubaker, P. L., Li, Q.-L., Perfetti, R., Jansen, E., Zambre, Y., Pipeleers, D., & Friedman, T. C. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7456 · Cited by 170
Relative quantitative analysis of glucagon receptor mRNA in rat tissues
Svoboda, M., Tastenoy, M., Vertongen, P., & Robberecht, P. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90162-7 · Cited by 169
Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Palatini, P., Casiglia, E., Pauletto, P., Staessen, J., Kaciroti, N., & Julius, S. (1997) · Hypertension · doi:10.1161/01.hyp.30.5.1267 · Cited by 165
Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164
Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
Hirata, K., Kume, S., Araki, S.-I., Sakaguchi, M., Chin-Kanasaki, M., Isshiki, K., Sugimoto, T., Nishiyama, A., Koya, D., Haneda, M., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.003 · Cited by 163
CD36 and lipid metabolism in the evolution of atherosclerosis
Zhao, L., Varghese, Z., Moorhead, J. F., Chen, Y., & Ruan, X. Z. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy006 · Cited by 161
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Ferdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E., Sager, P. T., Brunelle, R. L., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 155
Wilson, J. M., Lin, Y., Luo, M. J., Considine, G., Cox, A. L., Bowsman, L. M., Robins, D. A., Haupt, A., Duffin, K. L., & Ruotolo, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14553 · Cited by 149
Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 147
Self-citationKilimnik, G., Kim, A., Steiner, D. F., Friedman, T. C., & Hara, M. (2010) · Islets · doi:10.4161/isl.2.3.11396 · Cited by 143
Jensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Song, Y., Koehler, J. A., Baggio, L. L., Powers, A. C., Sandoval, D. A., & Drucker, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.009 · Cited by 140
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., Bacon, A., Jones, B. J., Lucey, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14309-w · Cited by 140
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stančáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 129
AMPK: a therapeutic target of heart failure—not only metabolism regulation
Li, X., Liu, J., Lü, Q., Ren, D., Sun, X., Rousselle, T. V., Tan, Y., & Li, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181767 · Cited by 128
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Nyberg, J., Jacobsson, C., Anderson, M. F., & Eriksson, P. S. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21349 · Cited by 117
The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
Baggio, L. L., Ussher, J. R., McLean, B. A., Cao, X., Kabir, M. G., Mulvihill, E. E., Mighiu, A. S., Zhang, H., Ludwig, A., Seeley, R. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.010 · Cited by 117
Self-citationGrunberger, G., Chang, A., Soria, G. G., Botros, F. T., Bsharat, R., & Miličević, Z. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03745.x · Cited by 107
Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 107
Self-citationBao, W., Aravindhan, K., Alsaid, H., Chendrimada, T., Szapacs, M., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 105
Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105
Bhashyam, S., Fields, A. V., Patterson, B., Testani, J. M., Chen, L., Shen, Y., & Shannon, R. P. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.900282 · Cited by 104
Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01584-3 · Cited by 102
Journal of Comparative Neurology
(2010) · The Journal of Comparative Neurology · doi:10.1002/(issn)1550-7130 · Cited by 102
Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96
Li, C., Yu, Q., Yu, P., Yu, T., Zhang, Q.-M., Lu, S., & Yu, D. M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-36 · Cited by 93
Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89
Timper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
Chen, S., Okahara, F., Osaki, N., & Shimotoyodome, A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00418.2014 · Cited by 88
McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
Editors, T. (2014) · Circulation · doi:10.1161/circulationaha.113.008229 · Cited by 84
Bellastella, G., Maiorino, M. I., Longo, M., Scappaticcio, L., Chiodini, P., Esposito, K., & Giugliano, D. (2020) · Stroke · doi:10.1161/strokeaha.119.027557 · Cited by 83
McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82
Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells
Zhong, Q., Bollag, R. J., Dransfield, D. T., Gasalla-Herraiz, J., Ding, K.-H., Min, L., & Isales, C. M. (2000) · Peptides · doi:10.1016/s0196-9781(00)00287-4 · Cited by 77
Richard, C. (1999) · Clinical Cardiology · doi:10.1002/clc.4960221102 · Cited by 77
Endocrinology, Diabetes and Metabolism Case Reports
(2013) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm · Cited by 77
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 74
Almutairi, M., Gopal, K., Greenwell, A. A., Young, A., Gill, R., Aburasayn, H., Al Batran, R., Chahade, J. J., Gandhi, M., Eaton, F., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.098 · Cited by 72
Dong, Z., Chai, W., Wang, W., Zhao, L., Fu, Z., Cao, W., & Liu, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2012 · Cited by 71
Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z. P., Chen, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.065 · Cited by 71
Hemodynamic Effects of Glucagon: A Literature Review
Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00050 · Cited by 68
Timper, K., Dalmas, E., Dror, E., Rütti, S., Thienel, C., Sauter, N. S., Bouzakri, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.003 · Cited by 67
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Kahles, F., Liberman, A., Halim, C., Rau, M., Möllmann, J., Mertens, R. W., Rückbeil, M. V., Diepolder, I., Walla, B., Diebold, S., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.014 · Cited by 66
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Aravindhan, K., Bao, W., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130894 · Cited by 59
The effect of liraglutide on endothelial function in patients with type 2 diabetes
Nandy, D., Johnson, C., Basu, R., Joyner, M., Brett, J., Svendsen, C. B., & Basu, A. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114547358 · Cited by 56
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 55
Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets
de Souza, A. H., Tang, J., Yadev, A. K., Saghafi, S. T., Kibbe, C. R., Linnemann, A. K., Merrins, M. J., & Davis, D. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-59799-2 · Cited by 54
Hiromura, M., Mori, Y., Kohashi, K., Terasaki, M., Shinmura, K., Negoro, T., Kawashima, H., Kogure, M., Wachi, T., Watanabe, R., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0152 · Cited by 51
Smith, C., Patterson-Cross, R., Woodward, O., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F., Reimann, F., & Adriaenssens, A. (2022) · Appetite · doi:10.1016/j.appet.2022.106022 · Cited by 47
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
Lenfant, C. J. M. (2001) · Circulation Research · doi:10.1161/01.res.88.3.253 · Cited by 44
Goldstein, R. E., Skelton, C. L., Levey, G. S., Glancy, D. L., BEISER, G. D., & Epstein, S. E. (1971) · Circulation · doi:10.1161/01.cir.44.4.638 · Cited by 43
Chepurny, O. G., Matsoukas, M., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005682 · Cited by 41
Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation
Cahill, K. N., Amin, T., Boutaud, O., Printz, R., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., et al. (2022) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.04.004 · Cited by 41
Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15875 · Cited by 41
Sassoon, D., Tune, J. D., Mather, K. J., Noblet, J. N., Eagleson, M. A., Conteh, A. M., Sturek, J. T., & Goodwill, A. G. (2017) · Diabetes · doi:10.2337/db16-1206 · Cited by 36
Darpö, B., Philip, S., MacConell, L., Cirincione, B., Mitchell, M., Han, J., Huang, W., Malloy, J., Schulteis, C., Shen, L., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04416.x · Cited by 35
The gut hormone receptor GIPR links energy availability to the control of hematopoiesis
Pujadas, G., Varin, E. M., Baggio, L. L., Mulvihill, E. E., Bang, K. W. A., Koehler, J. A., Matthews, D., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101008 · Cited by 35
Self-citationExendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3
Tsutsumi, Y. M., Tsutsumi, R., Hamaguchi, E., Sakai, Y., Kasai, A., Ishikawa, Y., Yokoyama, U., & Tanaka, K. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0132-9 · Cited by 35
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Caveolins in cardioprotection – translatability and mechanisms
Schilling, J. M., Roth, D. M., & Patel, H. H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.13009 · Cited by 34
Reversible dilated cardiomyopathy associated with glucagonoma
Chang-Chretien, K., Chew, J. T., & Judge, D. P. (2004) · Heart · doi:10.1136/hrt.2004.036905 · Cited by 34
Linnebjerg, H., Seger, M. E., Kothare, P. A., Hunt, T. L., Wolka, A. M., & Mitchell, M. I. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201462 · Cited by 32
Glucagon and Its Receptors in the Mammalian Heart
Neumann, J., Hofmann, B., Dhein, S., & Gergs, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612829 · Cited by 32
Morgen, C. S., Haase, C. L., Oral, T. K., Schnecke, V., Varbo, A., & Borlaug, B. A. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.07.008 · Cited by 32
Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure
Gao, C., Ren, S. V., Yu, J., Baal, U., Thai, D. L., Lu, J., Zeng, C., Yan, H., & Wang, Y. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.001 · Cited by 28
JACC: Basic to Translational Science
Mann, D. L. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.07.003 · Cited by 28
Karhunen, V., Daghlas, I., Zuber, V., Vujkovic, M., Olsen, A. K., Knudsen, L. B., Haynes, W. G., Howson, J. M. M., & Gill, D. (2021) · Diabetologia · doi:10.1007/s00125-021-05564-7 · Cited by 28
Kahles, F., Meyer, C., Diebold, S., Foldenauer, A. C., Stöhr, R., Möllmann, J., Lebherz, C., Findeisen, H. M., Marx, N., & Lehrke, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12711 · Cited by 25
Punjabi, M., Kosareva, A., Xu, L., Ochoa‐Espinosa, A., Decembrini, S., Hofmann, G., Wyttenbach, S., Rolin, B., Nyberg, M., & Kaufmann, B. A. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.08.002 · Cited by 25
Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
Darpo, B., Zhou, M., Matthews, J., Zhi, H., Young, M. A., Perry, C., & Reinhardt, R. R. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0055-1 · Cited by 24
CD36 expression in peripheral blood mononuclear cells reflects the onset of atherosclerosis
Yazgan, B., Sözen, E., Karademir-Yilmaz, B., Üstünsoy, S., İnce, Ü., Žarković, N., & Özer, N. K. (2017) · BioFactors · doi:10.1002/biof.1372 · Cited by 24
Al-Tubaikh, J. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-28575-2_3 · Cited by 22
Arteriosclerosis, Thrombosis, and Vascular Biology
(2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000028 · Cited by 21
Evans, M., Chandramouli, A. S., Faurby, M. D., Matthiessen, K. S., Mogensen, P. B., & Verma, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14703 · Cited by 21
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Loganathan, J., Cohen, A. C., Kaloupis, G. M., Harris, C., Chronopoulos, A., James, V., Hamilton, J. R., Green, S., Wallis, A., Morgan, S. J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108188 · Cited by 19
Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 18
Furusawa, S., Nomoto, H., Oba‐Yamamoto, C., Takeuchi, J., Ito, M., Kurihara, H., Aoki, S., Miya, A., Kameda, H., Nakamura, A., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0648 · Cited by 18
Glucagonoma-induced acute heart failure
Zhang, K., Lehner, L. J., Praeger, D., Baumann, G., Knebel, F., Quinkler, M. O., & Roepke, T. K. (2014) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0061 · Cited by 17
Terasaki, M., Yashima, H., Mori, Y., Saito, T., Shiraga, Y., Kawakami, R., Ohara, M., Fukui, T., Hirano, T., Yamada, Y., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070832 · Cited by 15
Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 14
Friedrichsen, M. H., Endahl, L. A., Kreiner, F. F., Goldwater, R., Kankam, M. K., Toubro, S., & Nygård, S. B. (2022) · medRxiv · doi:10.1101/2022.06.02.22275920 · Cited by 14
Evans, M., Husain, M., Srivastava, A., Mangla, K. K., Kuhlman, A. B., & Lingvay, I. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02750-4 · Cited by 13
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
Diabetes, Obesity and Metabolism
(2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12770 · Cited by 7
Emanuelli, E. (1958) · Tumori Journal · doi:10.1177/030089165804400509 · Cited by 6
Cited by
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Shah, E., Al-Shiab, R., Abdo, A., Özbek, L., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70713 · Cited by 17
Pereira, D. E., Tummala, S., Mittal, M. M., Obey, M. R., Berkes, M. B., McAndrew, C. M., & Wilson, J. L. (2025) · Injury · doi:10.1016/j.injury.2025.112746 · Cited by 15
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
“The administration of GLP-1R agonists in patients with T2D has achieved significantly lower hemoglobin A 1C (A 1C ) levels and promoted remarkable weight loss and significant cardiometabolic improvements [66].”
Zhou, Y., Tu, L., Wang, X., Xu, J., Xu, S., Ning, X., Xiong, X., & Zheng, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01399 · Cited by 10
Metadata
- Authors
- Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E.
- Affiliations
- University of Ottawa (CA)
- Ottawa Heart Institute (CA)
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2024-08-15
- Volume
- 263
- Issue
- 1
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- PMC
- PMC11466209
- OpenAlex
- W4401614784
- Semantic Scholar
- e704e36cb68ed5cba32d62ed23dd80a70996416a
- Cited by
- 51
- References
- 216
- Citations by year
- 2026: 36 · 2025: 15
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, cardiovascular risk, cardioprotection, type 2 diabetes, obesity, cardiovascular outcome trials, GIP/GLP-1 dual agonist, anti-obesity drugs, myocardial infarction, stroke, glycemia, blood pressure, postprandial lipemia, inflammation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.